BRD7 and endometrial cancer: Previous studies demonstrated that BRD7 delays tumor progression by negatively regulating the PI3K/AKT, P53, Ras-Raf-MEK-ERK, and β-catenin pathways [140,141,142,143], and a significant BRD7 downregulation was observed in breast, colon, lung, ovarian, and endometrial cancers [134,139,144,145,146].